Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cellsAna Valdehíta, Juan Carlos Prieto, Ana M. Bajo et al.|Molecular and Cellular Endocrinology|2008Cited by 56
Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancerAna Valdehíta, Marı́a J. Carmena, Eva Vacas et al.|Peptides|2010Cited by 54
Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cellsAna Valdehíta, Ana M. Bajo, Marı́a J. Carmena et al.|Regulatory Peptides|2007Cited by 35
RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cellsAna Valdehíta, Juan Carlos Prieto, Marı́a J. Carmena et al.|Molecular and Cellular Endocrinology|2011Cited by 30
Multifunctional role of VIP in prostate cancer progression in a xenograft model: Suppression by curcumin and COX-2 inhibitor NS-398Ana B. Fernández‐Martínez, Juan Carlos Prieto, Manuel Sánchez‐Chapado et al.|Peptides|2009Cited by 23